What is a stock summary page? Click here for an overview.
Business Description
Altamira Therapeutics Ltd
NAICS : 541714
SIC : 2834
ISIN : CH0408330303
Description
Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens. The company's OligoPhore / SemaPhore platform is a versatile system that allows the complexation of therapeutic RNAs with a proprietary peptide to form a nanoparticle formulation. This formulation allows to deliver of therapeutic RNA by systemic administration to tissues affected by leaky vasculature, a hallmark of solid tumors and certain inflammatory conditions.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.15 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.19 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | -22.25 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 87.3 | |||||
| 3-Year EPS without NRI Growth Rate | 84.7 | |||||
| 3-Year FCF Growth Rate | 90.9 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 56.79 | |||||
| 9-Day RSI | 50.97 | |||||
| 14-Day RSI | 48.1 | |||||
| 3-1 Month Momentum % | 24.6 | |||||
| 6-1 Month Momentum % | -84.73 | |||||
| 12-1 Month Momentum % | -95.65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.43 | |||||
| Quick Ratio | 0.43 | |||||
| Cash Ratio | 0.05 | |||||
| Days Inventory | 574.85 | |||||
| Days Sales Outstanding | 104.84 | |||||
| Days Payable | 2532.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -270.8 | |||||
| Shareholder Yield % | 1840.81 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 20.75 | |||||
| Operating Margin % | -1113.3 | |||||
| Net Margin % | -273.4 | |||||
| FCF Margin % | 2453.72 | |||||
| ROE % | -36.91 | |||||
| ROA % | -9.22 | |||||
| ROIC % | -37.48 | |||||
| 3-Year ROIIC % | -39.53 | |||||
| ROC (Joel Greenblatt) % | -693.35 | |||||
| ROCE % | -76.65 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 0.22 | |||||
| PE Ratio without NRI | 0.25 | |||||
| PS Ratio | 0.83 | |||||
| PB Ratio | 0.04 | |||||
| Price-to-Tangible-Book | 0.17 | |||||
| Price-to-Free-Cash-Flow | 0.03 | |||||
| Price-to-Operating-Cash-Flow | 0.03 | |||||
| EV-to-EBIT | -0.34 | |||||
| EV-to-Forward-EBIT | -0.26 | |||||
| EV-to-EBITDA | -0.35 | |||||
| EV-to-Revenue | 4.04 | |||||
| EV-to-FCF | 0.16 | |||||
| Price-to-Graham-Number | 0.04 | |||||
| Earnings Yield (Greenblatt) % | -294.12 | |||||
| FCF Yield % | 1161.96 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:CYTOF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Altamira Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.188 | ||
| EPS (TTM) ($) | 0.479 | ||
| Beta | 2.58 | ||
| 3-Year Sharpe Ratio | -1.42 | ||
| 3-Year Sortino Ratio | -1.91 | ||
| Volatility % | 75.53 | ||
| 14-Day RSI | 48.1 | ||
| 14-Day ATR ($) | 0.021278 | ||
| 20-Day SMA ($) | 0.101894 | ||
| 12-1 Month Momentum % | -95.65 | ||
| 52-Week Range ($) | 0.07 - 2.49 | ||
| Shares Outstanding (Mil) | 3.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Altamira Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Altamira Therapeutics Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Altamira Therapeutics Ltd Frequently Asked Questions
What is Altamira Therapeutics Ltd(CYTOF)'s stock price today?
The current price of CYTOF is $0.11. The 52 week high of CYTOF is $2.49 and 52 week low is $0.07.
When is next earnings date of Altamira Therapeutics Ltd(CYTOF)?
The next earnings date of Altamira Therapeutics Ltd(CYTOF) is .
Does Altamira Therapeutics Ltd(CYTOF) pay dividends? If so, how much?
Altamira Therapeutics Ltd(CYTOF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers